Suchergebnisse - "Urticaria"

PubPharm (10.019)

1

Yellow urticaria following plasma transfusion

enthalten in: The Journal of dermatology | 2024

von Pan, X. | Dong, Z.

2

A case of Schnitzler-like syndrome with basement membrane IgM deposition but without monoclonal gammopathy

enthalten in: JAAD case reports | 2024

von Ghali, H. | McClure, E. | Foster, E.

3

Disparities in chronic spontaneous urticaria : Eligibility for drug reimbursement associated with clinical outcomes

enthalten in: The journal of allergy and clinical immunology. Global | 2024

von Mak, H. | Chiang, V. | Chan, E. | +4

4

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib : A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies

enthalten in: ClinicalTrials.gov | 2024

5

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks. : A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

enthalten in: ClinicalTrials.gov | 2024

6

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines : A 52-week Multi-center, Randomized, Double-blind, Placebo Controlled, Basket Study With an Open-label Extension to Investigate the Efficacy, Safety, and Tolerability of Remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in Adults Inadequately Controlled by H1-antihistamines

enthalten in: ClinicalTrials.gov | 2024

7

A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients. : A Global, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib 25 mg b.i.d. in Comparison to Placebo With Omalizumab 300 mg Every 4 Weeks as Active Control Over 52 Weeks in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by Second-generation H1-antihistamines

enthalten in: ClinicalTrials.gov | 2024

8

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria : Study to Evaluate the Efficacy, Safety, Tolerability, and Immunogenicity of TEV-45779 Compared to XOLAIR (Omalizumab) in Patients With Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine (H1) Treatment.

enthalten in: ClinicalTrials.gov | 2024

9

To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria : A Multicenter, Randomized, Double-Blind, Positive Parallel Controlled Phase III Clinical Trial to Compare Omalizumab α(CMAB007) and Xolair® in Patients With Chronic Spontaneous Urticaria

enthalten in: ClinicalTrials.gov | 2024

10

Predicting responses to omalizumab in antihistamine-refractory chronic urticaria : A real-world longitudinal study

enthalten in: The journal of allergy and clinical immunology. Global | 2024

von Lee, H. | Jeon, H. | Jang, J. | +5

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[1002]